Evaluation of Drug-Drug Interaction Potential of Probuphine® Implants using a Physiologically-Based Pharmacokinetic Model
Presented by Titan Pharmaceuticals at the 10th American Conference on Pharmacometrics in Orlando, Florida, October 2019.
Posters
Population Pharmacokinetic Modeling and Exposure-Response Analysis of Probuphine® Implants in Opioid Use Disorder Subjects
Presented by Titan Pharmaceuticals at the 10th American Conference on Pharmacometrics in Orlando, Florida, October 2019.
Developing Long-term Malarial Chemoprophylactic Compound Releasing Implants
Presented at the Asia Pacific Military Health Exchange (APMHE), Singapore, May 2017.
Buprenorphine Implants for the Maintenance Treatment of Opioid Dependence: Twelve Month Outcomes
Presented at the American Association for the Treatment of Opioid Dependence conference in Philadelphia, Pennsylvania, November 2013.
Results of a Six-Month, Randomized, Controlled, Phase-3 Trial Comparing the Efficacy and Safety of Buprenorphine Implants to Placebo Implants, and Sublingual Buprenorphine/Naloxone for Opioid Addiction.
Presented at the American Society of Addiction Medicine (ASAM), Atlanta, Georgia, April 2012.
Results of a Six-Month, Randomized, Controlled, Phase 3 Trial Comparing the Efficacy and Safety Of Probuphine™ to Placebo Implants, and Suboxone® for Opioid Addiction
Presented by Titan Pharmaceuticals at the 13th annual meeting of International Society of Addiction Medicine (ISAM), Oslo, Norway, September 2011.
Safety, Efficacy, and Pharmacokinetics of Probuphine®, a 6-Month Implantable Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Addiction
Presented by Titan Pharmaceuticals at American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, December 2009.